



Dear editor,

Journal:	<i>The International Journal of Tuberculosis and Lung Disease</i>
Manuscript ID	Draft
Manuscript Type:	Correspondence
Date Submitted by the Author:	n/a
Complete List of Authors:	<p>van Crevel, Reinout; Radboud UMC, Internal Medicine; Andia Biraro, Irene; Makerere University, Internal Medicine; MRC/UVRI & LSHTM Uganda Research Unit, Immunomodulation and Vaccines Ntinginya, Nyanda Elias; NIMR-Mbeya Medical Research Center, Tuberculosis Chamba, Nyasatu; Kilimanjaro Christian Medical Centre, Internal Medicine Critchley, Julia; St George's University of London, Population health research institute Sharples, Katrina; University of Otago, Mathematics and Statistics Pennington, Mark; King's College London, King's Health Economics Kibirige, Davis; Uganda Martyrs Hospital, Lubaga, Medicine Manyama, Christina; NIMR-Mbeya Medical Research Center, Tuberculosis Kilonzo, Kajiru; Kilimanjaro Christian Medical Centre, Internal Medicine Sabi, Issa; National Institute for Medical Research, Mbeya Medical Research Centre te Brake, Lindsey ; Radboudumc, Pharmacy Hill, Philip; University of Otago, Centre for International Health</p>
Key Words:	diabetes, tuberculosis, preventive treatment, randomised controlled trial

SCHOLARONE™
Manuscripts

Dear Editor,


In a recent editorial Professor Anthony Harries made a plea for studies to assess the value of targeted TB preventive therapy among people with diabetes (DM).¹ We are happy to report that we will soon start the first randomised controlled trial globally to address this issue.

People with DM are an estimated 3.7 times more likely to develop TB than those without DM, this risk is higher with poorly controlled DM, and is likely to largely be due to high rates of reactivation of latent TB infection (LTBI).² It is estimated that DM now accounts for >10% of TB globally, and this will increase significantly in the coming decades due to the disproportionate rise in type 2 DM in TB endemic settings. DM not only increases someone's risk of developing TB disease, but is also associated with more severe TB disease, TB treatment failure, recurrent TB disease and death.³ Recently issued guidelines for TB and DM focus on screening patients with active TB for DM and on properly managing people with combined disease.^{4,5} This focus on screening and treatment of active disease may be clinically relevant but will have very little impact on the population burden of TB.

Treatment of latent tuberculosis infection (LTBI) among people with DM on the other hand, if proven safe and effective, would help improve TB control by reducing TB incidence in this large risk group. Preventive treatment among people with DM would also have significant indirect benefits: since DM is associated with higher TB bacillary loads (thus with more infectious forms of pulmonary TB), and higher treatment failure and recurrence rates,³ people with DM may be disproportionately responsible for onward community TB transmission. Indeed, a recent mathematical model of TB-DM in India estimated that LTBI preventive treatment targeted at people living with DM (assuming 50% uptake), could potentially prevent up to 11% of all population incident TB cases and 13% of TB-related mortality in the entire population, with even larger effects expected over the coming decades.⁶

To establish the first empiric evidence for LTBI management among people with DM, our PROTID study will randomize 3300 people with DM and LTBI in Tanzania and Uganda to a 12-week course of rifapentine and isoniazid preventive therapy or placebo, with cumulative incidence of TB disease over 24-months follow-up as the primary endpoint. While DM is with a relatively increased risk of developing LTBI,⁷ evidence suggests that the increased risk of TB in people with DM is largely from reactivation disease and a recent study from Indonesia found that among people with DM those with LTBI had a 3.5-fold higher TB incidence compared to those without LTBI.⁸ In parallel to the RCT we will follow a 1000 people with DM but without evidence of LTBI to confirm whether their incidence of TB in this group is indeed too low to warrant preventive treatment. In addition, PROTID will evaluate optimal ways to screen people with DM for LTBI and TB; address gaps in prevention and therapeutic management of combined TB and DM; and estimate the population impact and cost-effectiveness of treatment of LTBI in people living with DM on TB incidence and transmission (**figure**). This first study will take place in sub-Saharan Africa, which witnesses the fastest growth of type 2 DM including a large proportion with undiagnosed and poorly controlled DM.⁹ We have submitted a similar project for funding to be conducted in Asia, which currently carries the highest burden of combined TB and DM.¹⁰ If proven successful, these studies will provide crucial information to guide policy and practice regarding prevention and management of combined TB and DM.

Figure: conceptual overview of PROTID



PROTID ("Randomised Controlled Trial of Preventive Treatment of Latent Tuberculosis Infection in people with Diabetes Mellitus"), is part of the EDCTP2 programme, supported by the European Union (grant number RIA2018CO-2514-PROTID).

Reinout van Crevel (corresponding)

1. Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, the Netherlands
2. Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK

Irene Andia-Biraro, Makerere University, MRC/UVRI & LSHTM, Uganda

Nyanda Elias Ntinginya, National Institute for Medical Research - Tanzania (NIMR), Male, Tanzania, United Republic of

Nyasatu Chamba, Kilimanjaro Christian Medical Centre (KCMC), Tanzania, United Republic of

Julia Critchley, St. George's University of London, United Kingdom

Lindsey te Brake, Radboudumc (RUMC), Netherlands

Davis Kibirige, Uganda Martyrs Hospital Lubaga, Uganda

Christina Kisha Manyama, National Institute for Medical Research - Mbeya Medical Research Centre (NIMR-MMRC), Tanzania, United Republic of

Kajiru Kilonzo, Kilimanjaro Christian Medical Centre, Tanzania, United Republic

Mark Pennington, King's College London, United Kingdom

Katrina Sharples, University of Otago, New Zealand

Philip C Hill, University of Otago, New Zealand

- 1 Harries AD. Having diabetes and being underweight in Asia: a potent risk factor for tuberculosis. *int j tuberc lung dis* 2019; **23**: 1237-8.
- 2 Koesoemadinata R, McAllister SM, Soetedjo NN *et al.* Latent Tb infection and pulmonaery TB disease among patients with diabetes mellitus in Bandung, Indonesia. *Trans R Soc Trop Med Hyg* 2017
- 3 Huangfu P, Ugarte-Gil C, Golub J, Pearson F, Critchley J. The effects of diabetes on tuberculosis treatment outcomes: an updated systematic review and meta-analysis. *int j tuberc lung dis* 2019; **23**: 783–96.
- 4 van Crevel R, Koesoemadinata R, Hill PC, Harries AD. Clinical management of combined tuberculosis and diabetes. *int j tuberc lung dis* 2018; **22**: 1404–10.
- 5 Lin Y, Harries AD, Kumar AMV, *et al.* Tackling diabetes mellitus and tuberculosis: a new Union guide on the management of diabetes-tuberculosis. *int j tuberc lung dis* 2019; **23**: 771–2.
- 6 Awad SF, Critchley JA, Abu-Raddad LJ. Epidemiological impact of targeted interventions for people with diabetes mellitus on tuberculosis transmission in India: Modelling based predictions. *Epidemics* 2019; **30**: 100381.
- 7 Lee M-R, Huang Y-P, Kuo Y-T, *et al.* Diabetes Mellitus and Latent Tuberculosis Infection: A Systematic Review and Metaanalysis. *CLIN INFECT DIS* 2017; **64**: 719–27.
- 8 McAllister SM, Koesoemadinata RC, Santoso P, *et al.* High tuberculosis incidence among people living with diabetes in Indonesia. *Trans R Soc Trop Med Hyg* 2019; **12**: 457.
- 9 Atun R, Davies JI, Gale EAM, *et al.* Diabetes in sub-Saharan Africa: from clinical care to health policy. *Lancet Diabetes & Endocrinology* 2017; **5**: 622–67.
- 10 Noubiap JJ, Nansseu JR, Nyaga UF, *et al.* Global prevalence of diabetes in active tuberculosis: a systematic review and meta-analysis of data from 2·3 million patients with tuberculosis. *Lancet Glob Health* 2019; **7**: e448–60.